Boston Scientific Corporation (NYSE:BSX) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Boston Scientific Corporation has received a consensus recommendation of "Buy" from 26 research firms, with an average 1-year price target of $118.04.
• Several analysts, including Robert W. Baird and Barclays, have recently raised their target prices for Boston Scientific, with Barclays setting a new target at $133.00.
• Insider activity shows significant sales, with an executive selling 17,313 shares and a director selling 2,901 shares, indicating a 42.32% and 58.23% decrease in their ownership, respectively.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) has earned a consensus rating of "Buy" from the twenty-six research firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation, twenty-two have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $118.0417.

Several research analysts have weighed in on the company. Raymond James Financial boosted their price target on Boston Scientific from $121.00 to $124.00 and gave the company a "strong-buy" rating in a report on Thursday, July 24th. Royal Bank Of Canada reissued an "outperform" rating on shares of Boston Scientific in a research report on Thursday, July 24th. Barclays upped their target price on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Robert W. Baird increased their price objective on shares of Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Finally, Leerink Partners initiated coverage on shares of Boston Scientific in a research note on Monday, June 16th. They set an "outperform" rating and a $118.00 price objective on the stock.

Boston Scientific Price Performance

NYSE:BSX traded down $0.39 during trading hours on Friday, reaching $97.84. 16,833,754 shares of the company traded hands, compared to its average volume of 8,034,038. The firm's 50-day moving average is $104.40 and its 200-day moving average is $102.09. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The stock has a market cap of $144.97 billion, a P/E ratio of 58.24, a P/E/G ratio of 2.36 and a beta of 0.65. Boston Scientific has a 1-year low of $80.64 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.Boston Scientific's revenue was up 22.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities research analysts expect that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, Director Yoshiaki Fujimori sold 2,901 shares of the firm's stock in a transaction that occurred on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the sale, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $105.43, for a total transaction of $5,271,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares in the company, valued at $18,802,597.06. The trade was a 21.90% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 174,214 shares of company stock worth $18,397,457 in the last ninety days. Insiders own 0.50% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in shares of Boston Scientific by 72.9% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 344 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 145 shares in the last quarter. Valeo Financial Advisors LLC boosted its holdings in shares of Boston Scientific by 4.3% in the second quarter. Valeo Financial Advisors LLC now owns 22,551 shares of the medical equipment provider's stock valued at $2,422,000 after acquiring an additional 930 shares in the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Boston Scientific by 20.0% in the second quarter. Osaic Holdings Inc. now owns 144,745 shares of the medical equipment provider's stock valued at $15,459,000 after acquiring an additional 24,080 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Boston Scientific by 44.1% in the second quarter. China Universal Asset Management Co. Ltd. now owns 26,576 shares of the medical equipment provider's stock valued at $2,855,000 after acquiring an additional 8,139 shares in the last quarter. Finally, Orion Porfolio Solutions LLC boosted its holdings in shares of Boston Scientific by 9.5% in the second quarter. Orion Porfolio Solutions LLC now owns 36,550 shares of the medical equipment provider's stock valued at $3,926,000 after acquiring an additional 3,165 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.